lencana Anda Rentang 52M $22–$46 40% of range Peringkat Analis BUY 16 analysts Target Harga $46 +45% upside P/E -4.5 ROE -34.3% Margin Laba Bersih -418.2%

AGIO Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $31.80
Kapitalisasi Pasar (MRQ) $1.90B
P/E (TTM) -4.5
EPS (TTM) $-7.02
Pendapatan (TTM) $98M
ROE (TTM) -34.3%
Rentang 52M $22–$46

AGIO Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Tentang Agios Pharmaceuticals, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

History

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.

In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.

In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration.

In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.

In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency.

Corporate governance

As of August 2022, Agios' CEO is Brian Goff.

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.

== References ==

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriBiotechnology karyawan539 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$54M
2016-12-31 → 2025-12-31
EPS$-7.12
2019-12-31 → 2025-12-31
Arus Kas Bebas$-377M
2016-12-31 → 2025-12-31
Margin bersih-418.2%
2017-12-31 → 2025-12-31
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun AGIO rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) -4.5rata-rata 5T ≈-2.0 ≈-2.0 · ·
P/S (TTM) 19.3rata-rata 5T ≈59.0 ≈59.0 25.9 Nilai wajar
P/B (MRQ) 1.8rata-rata 5T ≈1.4 ≈1.4 6.0 Kurang nilai
Harga / FCF (TTM) -5.2rata-rata 5T ≈-4.5 ≈-4.5 · ·
Harga / Arus Kas (TTM) -5.3rata-rata 5T ≈-4.5 ≈-4.5 · ·
Price / Tangible Book (Harga / Nilai Buku Berwujud) 2013.9rata-rata 5T ≈1.4 ≈1.4 · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata 5.5%
Laporan Berikutnya Okt 28, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Jul 29, 2026 $-1.69 $-1.70 0.66%
31 Maret 2026 $-1.69 $-1.84 8.0%
31 Des. 2025 $-1.86 $-1.99 6.3%
30 Sep. 2025 $-1.78 $-1.94 8.1%
30 Juni 2025 $-1.93 $-1.84 -4.7%
31 Maret 2025 $-1.55 $-1.82 14.8%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 16
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $54M$36M$27M$14M$0$0$118M$94M$43M$70M$59M$65M
Cost of Revenue $6M$4M$3M$2M$0$0$1M$1M$0$0··
R&D Expense $340M$301M$296M$280M$257M$221M$214M$341M$293M$220M$142M$100M
SG&A Expense $180M$157M$120M$122M$121M$115M$102M$114M$71M$51M$36M$19M
Operating Expenses $526M$462M$418M$403M$378M$336M$316M$457M$364M$271M$178M$119M
Operating Income $-472M$-426M$-391M$-389M$-378M$-336M$-316M$-362M$-321M$-201M$-119M$-54M
Interest Income ···$13M$836.0K$7M$15M$16M$6M$3M$968.0K$203.0K
Other Non-op $2M$6M$6M$7M$14M$0$0·····
Pretax Income $-414M$718M$-352M$-232M$-357M$-329M$-301M$-346M$-315M$-198M$-118M$-54M
Income Tax $-1M$44M$0$0··$0$0$0$0$0$-426.0K
Net Income $-413M$674M$-352M$-232M$1.60B$-327M$-411M$-346M$-315M$-198M$-118M$-54M
EPS (Basic) $-7.12$11.86$-6.33$-4.23$26.55$-4.74$-6.86·····
EPS (Diluted) $-7.12$11.64$-6.33$-4.23$26.55$-4.74$-6.86·····
Shares (Basic) 57,972,00456,807,41555,651,48754,789,43560,447,34668,997,87959,994,539·····
Shares (Diluted) 57,972,00457,889,25555,651,48754,789,43560,447,34668,997,87959,994,539·····
EBITDA $-472M$-426M$-391M$-389M$-378M$-316M$-418M$-362M$-321M$-201M$-119M$-54M
Neraca 22
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $89M$76M$88M$139M$203M$127M$81M$71M$103M$161M$72M$14M
Short-term Investments ·······$515M$321M$381M··
Inventory $33M$28M$19M$8M$0$15M$7M$869.0K$0···
Prepaid Expense $44M$40M$35M$39M$40M$16M$24M$17M$18M$10M$9M$5M
Current Assets $942M$966M$834M$833M$1.06B$637M$612M$614M$445M$560M$337M$360M
PP&E (Net) $11M$12M$15M$23M$29M$31M$31M$24M$24M$25M$23M$6M
PP&E (Gross) $71M$68M$68M$73M$74M$72M$64M$50M$44M$39M$31M$12M
Accum. Depreciation $60M$56M$52M$50M$45M$41M$32M$26M$19M$13M$8M$6M
Other Non-current Assets $4M$5M$4M$4M$3M$0$0$238.0K$891.0K$2M$611.0K$590.0K
Total Assets $1.30B$1.66B$937M$1.24B$1.44B$853M$891M$858M$614M$619M$420M$492M
Accounts Payable $18M$17M$10M$19M$17M$18M$22M$18M$23M$17M$15M$11M
Accrued Liabilities $45M$47M$43M$30M$32M$31M$53M$42M$34M$32M$16M$14M
Current Liabilities $82M$81M$68M$63M$60M$94M$93M$94M$95M$88M$53M$61M
Capital Leases $22M$40M$57M$72M$86M$97M$106M·····
Other Non-current Liabilities $90.0K$880.0K$1M$3M$0·······
Total Liabilities $104M$122M$126M$138M$146M$453M$250M$171M$239M$261M··
Common Stock ····$71.0K$69.0K$68.0K$58.0K$49.0K$42.0K$38.0K$37.0K
Retained Earnings $-562M$-149M$-823M$-471M$-239M$-1.84B$-1.52B$-1.10B$-798M$-483M$-285M$-167M
Treasury Stock $802M$802M$802M$802M$802M$0······
Stockholders' Equity $1.19B$1.54B$811M$1.10B$1.29B$400M$641M$688M$376M$359M$345M$424M
Liabilities + Equity $1.30B$1.66B$937M$1.24B$1.44B$853M$891M$858M$614M$619M$420M$492M
Shares Outstanding 58,448,59273,372,696,00072,161,48971,256,11870,550,63169,293,92068,401,10558,218,65348,826,15342,220,44437,696,50237,100,513
Arus Kas 13
Metrik Tren 202520242023202220212020201920182017201620152014
D&A ······$8M$7M$6M···
Stock-based Comp $53M$43M$45M$49M$54M$62M$58M$73M$48M$42M$32M$12M
Deferred Tax ·········$0$0$0
Other Non-cash ······$-40M·····
Operating Cash Flow $-373M$-390M$-296M$-309M$-407M$-291M$-371M$-304M$-285M$39M$-77M$-59M
CapEx $4M$2M$999.0K$5M$6M$14M$12M$7M$5M$10M$20M$2M
Investing Cash Flow $377M$363M$240M$243M$1.25B$76M$91M$-274M$-58M$-119M$128M·
Stock Issued ····$0$0$277M$516M$270M$162M$0$334M
Net Stock Activity ····$0$0$277M$516M$270M$162M·$334M
Financing Cash Flow $9M$14M$5M$2M$-766M$262M$290M$546M$285M$170M$6M·
Net Change in Cash $13M$-12M$-51M$-64M$76M$47M$10M$-32M$-58M$89M$58M$-58M
Taxes Paid $628.0K$43M$2M·········
Free Cash Flow $-377M$-392M$-297M$-314M$-413M$-306M$-383M$-311M$-290M$29M$-97M$-62M
Profitabilitas 7
Metrik Tren 202520242023202220212020201920182017201620152014
Operating Margin -873.9%-1166.5%-1459.5%-2732.1%·-155.6%-361.6%·-745.8%··-82.8%
Net Margin -764.0%1845.9%-1312.6%-1627.8%·-161.1%-349.0%·-731.6%··-81.9%
Pretax Margin -765.9%1967.2%-1312.6%-1627.8%·-161.2%-349.0%·-731.6%··-82.5%
EBITDA Margin -873.9%-1166.5%-1459.5%-2732.1%·-155.6%-354.7%·-745.8%··-82.8%
ROA -27.9%51.8%-32.4%-17.3%140.1%-37.5%-47.0%-47.0%-51.0%-38.2%-25.8%-15.4%
ROE -32.2%42.5%-41.5%-21.6%119.4%-74.4%-75.6%-47.8%-85.7%-56.4%-30.6%-19.2%
ROIC -39.5%-25.9%····-66.6%-52.7%-85.4%··-12.7%
Likuiditas & Solvabilitas 2
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 11.511.912.313.317.86.76.66.64.76.36.45.9
Quick Ratio 1.10.91.32.23.41.40.96.34.51.81.40.2
Efisiensi 2
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 0.00.00.00.0·0.20.1·0.1··0.2
Inventory Turnover 0.20.20.20.4·0.30.33.2····
Per Saham 5
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share $20.41$26.96$14.50$20.00$23.78$5.77$9.36$11.81$7.69$8.49$9.16$11.44
Revenue / Share $0.93$0.63$0.48$0.26········
Cash Flow / Share $-6.43$-6.73$-5.32$-5.65$-6.74·······
Cash / Share $1.52$1.33$1.58$2.53$3.74$1.84$1.18$1.21$2.10$3.81$1.90$0.38
EPS (TTM) $-7.12$11.64$-6.33$-4.23$26.55$-4.74$-6.86····$-1.59
Tingkat Pertumbuhan 4
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY 48.0%36.1%88.4%·········
Revenue CAGR 3Y 56.0%···········
EPS CAGR 3Y ·-24.0%··········
Net Income CAGR 3Y ·-25.1%··········
Valuasi (TTM) 10
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $54M$36M$27M$14M$0$0$118M$94M$43M$70M$59M$65M
Net Income TTM $-413M$674M$-352M$-232M$1.60B$-327M$-411M$-346M$-315M$-198M$-118M$-54M
Market Cap $1.59B$1.88B$1.25B$1.55B$1.79B$3.00B$3.27B$2.68B$2.79B$1.76B$2.45B$4.16B
P/E -3.82.8-3.5-6.61.2-9.1-7.0····-70.5
P/S 29.451.546.4108.5··27.728.464.925.241.463.6
P/B 1.31.21.51.41.47.55.13.97.44.97.19.8
P / Tangible Book 1.31.21.51.41.47.5······
P / Cash Flow -4.3-4.8-4.2-5.0-4.4-10.3-8.8-8.8-9.845.7-31.8-70.0
P / FCF -4.2-4.8-4.2-4.9-4.3-9.8-8.5-8.6-9.661.5-25.2-67.5
Earnings Yield -26.2%35.4%-28.4%-15.1%80.8%-10.9%-14.4%····-1.4%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $54M $36M $27M $14M $0
Margin Operasi % -873.9% -1166.5% -1459.5% -2732.1% ·
Laba Bersih $-413M $674M $-352M $-232M $1.60B
EPS Dilusian $-7.12 $11.64 $-6.33 $-4.23 $26.55

Pemilik institusional (13F) 262 pengaju · $2.7B total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 262
Nilai yang dipegang $2.7B
Posisi baru 39
Posisi yang keluar 30
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
39 (-2 vs Kuartal sebelumnya) 30 (-2 vs Kuartal sebelumnya) 96 (+16 vs Kuartal sebelumnya) 69 (-19 vs Kuartal sebelumnya) +8.4M

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
BlackRock, Inc. $239.582.050 6.455.997 8,88% Saham
FARALLON CAPITAL MANAGEMENT, L.L.C. $219.594.714 5.917.400 8,14% Saham
VANGUARD GROUP INC $152.278.288 5.594.353 5,64% Saham
STATE STREET CORP $131.144.972 3.533.633 4,86% Saham
Lynx1 Capital Management LP $126.505.652 3.408.937 4,69% Saham
D. E. Shaw & Co., Inc. $115.300.956 3.107.005 4,27% Saham
VANGUARD PORTFOLIO MANAGEMENT LLC $107.552.091 2.898.197 3,98% Saham
ARMISTICE CAPITAL, LLC $104.279.100 2.810.000 3,86% Opsi beli
VANGUARD CAPITAL MANAGEMENT LLC $99.523.268 2.681.845 3,69% Saham
ARMISTICE CAPITAL, LLC $89.064.000 2.400.000 3,30% Saham
Erste Asset Management GmbH $81.972.396 2.154.900 3,04% Saham
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $78.332.000 2.110.809 2,90% Saham
GEODE CAPITAL MANAGEMENT, LLC $58.433.490 1.574.268 2,17% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $51.046.957 1.375.558 1,89% Saham
ADAR1 Capital Management, LLC $47.799.647 1.288.053 1,77% Saham
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $47.502.433 1.280.044 1,76% Saham
DIMENSIONAL FUND ADVISORS LP $46.345.467 1.248.738 1,72% Saham
GOLDMAN SACHS GROUP INC $42.711.087 1.150.932 1,58% Saham
UBS Group AG $36.584.189 985.831 1,36% Saham
MORGAN STANLEY $35.746.487 963.256 1,32% Saham
Nuveen, LLC $32.417.811 873.560 1,20% Saham
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $30.078.768 810.530 1,11% Saham
Foresite Capital Management VI LLC $29.131.350 785.000 1,08% Saham
CITADEL ADVISORS LLC $27.190.015 732.687 1,01% Saham
AQR CAPITAL MANAGEMENT LLC $25.395.858 684.340 0,94% Saham
Parkman Healthcare Partners LLC $24.828.297 669.046 0,92% Saham
SCS Capital Management LLC $22.742.864 612.850 0,84% Saham
Qube Research & Technologies Ltd $22.178.346 597.638 0,82% Saham
NORTHERN TRUST CORP $20.585.250 554.709 0,76% Saham
Defilade Capital Management, L.P. $20.293.529 546.848 0,75% Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $19.969.930 538.128 0,74% Saham
TWO SIGMA INVESTMENTS, LP $19.905.062 536.380 0,74% Saham
Rock Springs Capital Management LP $19.763.413 532.563 0,73% Saham
Schonfeld Strategic Advisors LLC $19.300.279 520.083 0,72% Saham
BANK OF AMERICA CORP /DE/ $18.847.034 507.869 0,70% Saham
Point72 Asset Management, L.P. $18.790.426 506.344 0,70% Saham
JANE STREET GROUP, LLC $18.280.312 492.598 0,68% Saham
Legal & General Group Plc $16.132.422 434.719 0,60% Saham
VANGUARD FIDUCIARY TRUST CO $14.690.661 395.868 0,54% Saham
PANAGORA ASSET MANAGEMENT INC $13.876.579 373.931 0,51% Saham
KENNEDY CAPITAL MANAGEMENT LLC $13.850.565 373.230 0,51% Saham
JPMORGAN CHASE & CO $13.783.528 359.756 0,51% Saham
Connor, Clark & Lunn Investment Management Ltd. $13.342.901 359.550 0,49% Saham
Squarepoint Ops LLC $11.917.431 321.138 0,44% Saham
Ensign Peak Advisors, Inc $11.045.049 297.630 0,41% Saham
BNP PARIBAS FINANCIAL MARKETS $9.996.803 269.383 0,37% Saham
ALGERT GLOBAL LLC $9.203.540 248.007 0,34% Saham
JANE STREET GROUP, LLC $7.974.939 214.900 0,30% Opsi jual
Palo Alto Investors LP $7.926.733 213.601 0,29% Saham
Tetragon Partners GP Ltd $7.629.037 205.579 0,28% Saham

Tampilkan semua 262 pemilik institusional →

Aktivis & pemilik 5%+ 3 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION, CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC 5 April 2021 · Pengajuan awal · SEC
CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 pengajuan 14 Nov. 2019 · Pengajuan awal Struktur modal SEC
CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 pengajuan 17 Des. 2014 · Pengajuan awal Struktur modal SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 38 orang dalam · 18 pejabat · 20 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Brian Goff Chief Executive Officer 18 Juni 2026 A 184.508 0 7 $-1.691.387
Cecilia Jones Chief Financial Officer 18 Juni 2026 A 54.998 0 6 $-334.266
Jonathan Biller Chief Financial Officer 1 Maret 2022 A 22.953 0 0 $0
Andrew Hirsch Chief Financial Officer 22 April 2020 M 24.272 0 0 $0
John Duncan Higgons Chief Operating Officer 4 Jan. 2016 M 120.834 0 0 $0
Sarah Gheuens Chief Medical Officer 4 Agu 2026 S 54.645 0 10 $-1.625.034
Krishnan Viswanadhan Chief Strategy and Operations 18 Juni 2026 A 10.282 0 2 $-184.967
Tsveta Milanova Chief Commercial Officer 18 Juni 2026 A 46.829 0 5 $-353.311
James William Burns Chief Legal Officer 18 Juni 2026 A 49.306 0 6 $-344.391
Theodore James Washburn Jr. Principal Accounting Officer 3 Maret 2026 S 868 0 4 $-216.633
Richa Poddar Chief Commercial Officer 15 Okt. 2022 M 8.508 0 0 $0
Bruce Car Chief Scientific Officer 1 Maret 2022 A 16.752 0 0 $0
Carman Alenson Principal Accounting Officer 21 Juni 2021 M 0 0 0 $0
Christopher Bowden Chief Medical Officer 18 Juni 2021 M 15.487 0 0 $0
Darrin Miles Chief Commercial Officer 14 Mei 2021 S 7.209 0 0 $0
Scott Biller Chief Scientific Officer 11 Juni 2019 M 33.729 0 0 $0
Steven L. Hoerter Chief Commercial Officer 4 Maret 2019 M 10.941 0 0 $0
Glenn Goddard Senior Vice President, Finance 16 Feb. 2016 A 0 0 0 $0
Jay T. Backstrom Direktur 8 Juli 2026 M 1.447 0 0 $0
Adams Catherine Owen Direktur 18 Juni 2026 A 10.865 0 0 $0
Rahul D. Ballal Direktur 18 Juni 2026 A 15.230 0 0 $0
David Scadden Direktur 18 Juni 2026 A 20.419 0 2 $-16.968
Maykin Ho Direktur 18 Juni 2026 A 19.848 0 0 $0
Cynthia Smith Direktur 18 Juni 2026 A 15.230 0 0 $0
Jacqualyn A Fouse Direktur 18 Juni 2026 A 154.156 0 0 $0
Kaye I Foster-Cheek Direktur 18 Juni 2026 A 10.284 0 0 $0
Jeffrey D Capello Direktur 18 Juni 2026 A 10.865 0 0 $0
David P Schenkein Direktur 20 Juni 2024 A 126.242 0 0 $0
Paul J Clancy Direktur 21 Juni 2022 A 6.549 0 0 $0
John Maraganore Direktur 21 Juni 2022 A 30.028 0 0 $0
Ian T Clark Direktur 20 Mei 2022 M 6.549 0 0 $0
Lewis Clayton Cantley Jr. Direktur 7 Des. 2017 S 79.515 0 0 $0
Robert Nelsen Direktur 6 Maret 2017 S 0 0 0 $0
Douglas G. Cole Direktur 10 Agu 2016 J 2.778 0 0 $0
Marc Tessier-Lavigne Direktur 21 Juni 2016 A 101.009 0 0 $0
Perry A Karsen Direktur 23 Juni 2015 A · 0 0 $0
Kevin P Starr Direktur 19 Feb. 2015 J 184.386 0 0 $0
Celgene European Investment Co LLC Pemilik 10% 16 Des. 2014 P 1.231.778 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 43 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
BBP · ETFis Series Trust I 1,40% 46.067 NS 31 Juli 2026 N-PORT
HAPS · Harbor ETF Trust 0,82% 46.575 NS 31 Juli 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0,50% 3.546 SH 2 Okt. 2026 Harian
LABU · Direxion Shares ETF Trust 0,41% 67.945 NS 31 Juli 2026 N-PORT
FYC · First Trust Exchange-Traded AlphaDE… 0,32% 139.210 NS 31 Juli 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,22% 17.481 SH 2 Okt. 2026 Harian
PRFZ · Invesco Exchange-Traded Fund Trust 0,15% 119.054 SH 2 Okt. 2026 Harian
IBB · iShares Trust 0,14% 425.302 SH 11 Sep. 2026 Harian
VTWV · VANGUARD SCOTTSDALE FUNDS 0,13% 48.730 SH 19 Agu 2026 Harian
IBBQ · Invesco Exchange-Traded Fund Trust … 0,13% 4.219 SH 2 Okt. 2026 Harian
PWS · Pacer Funds Trust 0,12% 928 NS 31 Juli 2026 N-PORT
FYX · First Trust Exchange-Traded AlphaDE… 0,10% 47.013 NS 31 Juli 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,07% 340.226 SH 19 Agu 2026 Harian
FAD · First Trust Exchange-Traded AlphaDE… 0,07% 12.610 NS 31 Juli 2026 N-PORT
IWM · iShares Trust 0,07% 1.511.496 SH 11 Sep. 2026 Harian
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0,07% 15.124 NS 31 Juli 2026 N-PORT
ESML · iShares Trust 0,06% 50.007 SH 11 Sep. 2026 Harian
VBK · VANGUARD INDEX FUNDS 0,06% 788.655 SH 19 Agu 2026 Harian
RSSL · Global X Funds 0,06% 28.271 NS 31 Juli 2026 N-PORT
DFAS · Dimensional ETF Trust 0,04% 192.387 NS 31 Juli 2026 N-PORT
ISCG · iShares Trust 0,04% 10.228 SH 11 Sep. 2026 Harian
DXUV · Dimensional ETF Trust 0,03% 5.807 NS 31 Juli 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0,03% 1.364.364 SH 19 Agu 2026 Harian
VHT · VANGUARD WORLD FUND 0,03% 167.169 SH 19 Agu 2026 Harian
FHLC · FIDELITY COVINGTON TRUST 0,02% 26.897 NS 31 Juli 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,02% 683.802 SH 19 Agu 2026 Harian
WSML · iShares Trust 0,02% 3.364 SH 11 Sep. 2026 Harian
VTWG · VANGUARD SCOTTSDALE FUNDS 0,01% 3.639 SH 19 Agu 2026 Harian
DFAC · Dimensional ETF Trust 0,01% 148.210 NS 31 Juli 2026 N-PORT
DCOR · Dimensional ETF Trust 0,01% 9.209 NS 31 Juli 2026 N-PORT
IWO · iShares Trust 0,01% 31.737 SH 11 Sep. 2026 Harian
TILT · FlexShares Trust 0,01% 4.553 NS 31 Juli 2026 N-PORT
DFAU · Dimensional ETF Trust 0,00% 17.627 NS 31 Juli 2026 N-PORT
IWV · iShares Trust 0,00% 16.716 SH 11 Sep. 2026 Harian
ITOT · iShares Trust 0,00% 76.792 SH 11 Sep. 2026 Harian
DFUS · Dimensional ETF Trust 0,00% 17.217 NS 31 Juli 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0,00% 1.890.189 SH 19 Agu 2026 Harian
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,00% 46.943 SH 19 Agu 2026 Harian
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 4.834 SH 19 Agu 2026 Harian
ESGV · VANGUARD WORLD FUND 0,00% 13.097 SH 19 Agu 2026 Harian
IWN · iShares Trust · 521.555 SH 11 Sep. 2026 Harian
ISCB · iShares Trust · 2.551 SH 11 Sep. 2026 Harian
ISCV · iShares Trust · 5.020 SH 11 Sep. 2026 Harian

AGIO Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 16 analis BELI
Target median $44.50 +39,9%
5 31,2% Beli Kuat
7 43,8% Beli
4 25,0% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

8 analis · 2026-10-04

Target rata-rata $46.25 +45,4%

← Di bawah semua target Harga saat ini $31.80
Rendah$32.00 Rata-rata$46.25 Tinggi$73.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
AGIO $1.59B -3.8 48.0% -764.0% -32.2% ·
MLYS $2.96B -15.8 · · -32.2% ·
BCRX $1.66B 6.4 94.1% 30.2% -97.6% ·
ZBIO $1.98B -4.3 100.0% -3777.4% -156.8% ·
VCEL $1.82B 112.5 16.4% 6.0% 5.0% 74.4%
BHVN $1.50B -1.6 · · -310.8% ·
VIR $841M -1.9 -7.6% -638.9% -51.1% ·
PVLA $1.30B -28.2 65.3% -1610.6% -110.1% ·
ABSI $529M -4.2 -38.2% -4113.7% -63.5% ·
SRPT $2.26B -3.0 15.6% -32.5% -57.1% ·
GENB · · · · · ·

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23
Peringatan Kekuatan Relatif Untuk Agios Pharmaceuticals Nasdaq · 5 bulan lalu Chief Medical Officer Maze Therapeutics Menjual 100% Kepemilikan Langsungnya. Inilah Artinya Bagi Investor. Nasdaq · 5 bulan, 4 minggu lalu

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Jul 30, 2026